Prevalence of polymorphisms in the ANKK1, DRD2, DRD3 genes and metabolic syndrome in refractory schizophrenia.
Jeizziani Aparecida Ferreira Pinto, Pedro Henrique Batista de Freitas, Fernanda Daniela Dorneles Nunes and 3 others
PMID 29791666WHAT IT FOUND
The three tested dopamine gene variants were not associated with metabolic syndrome in 72 people with refractory schizophrenia on clozapine.
Metabolic syndrome was common, but these results do not support using these variants to predict it.
Key findings
01The studied polymorphisms were not associated with metabolic syndrome overall.
02Metabolic syndrome was present in 47.2% of the 72 patients.
03In a secondary analysis of metabolic syndrome components, low HDL was associated with the homozygous Ins C genotype of the -141C polymorphism, with an odds ratio of 19.8 and a 95% confidence interval of 1.51 to 701.1.
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The sample was not probabilistic, and the authors caution against generalizing the results. The cross-sectional design cannot show cause and effect. The odds ratio for the low HDL association had a very wide confidence interval, from 1.51 to 701.1. Participants had to have understanding capacity on the MMSE and excluded physical disability that could impair anthropometric measurement, so the findings may not apply to more impaired patients.
The easy way to misread this
Do not conclude that these gene variants can identify patients at risk of metabolic syndrome or guide clozapine treatment. The overall association with metabolic syndrome was not significant, and the low HDL finding was a secondary analysis with an odds ratio of 19.8 and a 95% confidence interval from 1.51 to 701.1.